C:\Program Files\Stnexp\Queries\10770382.str





chain nodes :
7 8 10 20 22 23 27
ring nodes :
1 2 3 4 5 11 12 13 14 15 16
chain bonds :
1-8 2-22 4-7 5-10 10-12 22-27 23-27
ring bonds :
1-2 1-5 2-3 3-4 4-5 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
1-2 1-5 1-8 2-3 2-22 3-4 4-5 4-7 5-10 23-27
exact bonds :
10-12 22-27
normalized bonds :
11-12 11-16 12-13 13-14 14-15 15-16
isolated ring systems :
containing 1 :

G1:O,NH

G2:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 8:CLASS 10:CLASS 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom

16:Atom 20:CLASS 21:Atom 22:CLASS 23:Atom 27:CLASS

=>
Uploading C:\Program Files\Stnexp\Queries\10770382.str





chain nodes :
7 8 10 20 22 23 27
ring nodes :
1 2 3 4 5 11 12 13 14 15 16
chain bonds :
1-8 2-22 4-7 5-10 10-12 22-27 23-27
ring bonds :
1-2 1-5 2-3 3-4 4-5 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
1-2 1-5 1-8 2-3 2-22 3-4 4-5 4-7 5-10 23-27
exact bonds :
10-12 22-27
normalized bonds :
11-12 11-16 12-13 13-14 14-15 15-16
isolated ring systems :
containing 1 :

G1:O,NH

G2:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 8:CLASS 10:CLASS 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 20:CLASS 21:Atom 22:CLASS 23:Atom
27:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 18:36:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 14789 TO ITERATE

13.5% PROCESSED 2000 ITERATIONS 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 288496 TO 303064
PROJECTED ANSWERS: 65 TO 525

L2 2 SEA SSS SAM L1

=> => s l1 sss ful
FULL SEARCH INITIATED 18:37:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 295149 TO ITERATE

100.0% PROCESSED 295149 ITERATIONS 257 ANSWERS
SEARCH TIME: 00.00.04

L3 257 SEA SSS FUL L1

=> => s l3
L4 17 L3

=> d l4 1-17 bib,ab,hitstr

L4 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:91438 CAPLUS
DN 144:192246
TI Preparation of imidazolidinediones as protein kinase inhibitors
IN Strobel, Hartmut; Nemecek, Conception; Lesuisse, Dominique; Ruf, Sven; El-Ahmad, Youssef; Guessregen, Stefan; Lebrun, Anne; Ritter, Kurt; Benard, Didier; Hittinger, Augustin; Bouchard, Herve
PA Aventis Pharma S. A., Fr.
SO Eur. Pat. Appl., 82 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1621536	A1	20060201	EP 2004-291904	20040727
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	WO 2006010641	A2	20060202	WO 2005-EP8720	20050725
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	EP 2004-291904	A	20040727		

OS MARPAT 144:192246
AB Title compds. [I; p = 0-2; A = (substituted) aryl, heteroaryl, carbocycle, heterocycle; X = bond, NR6, O, CO, SOn, NR6CO, NR6CONR6', NR6CSNR6', NR6CO2, NR6SO2, NR6SO2NR6', CONR6, SO2NR6, CO2; L1 = (substituted) alkylene, alkenylene, alkynylene, cycloalkylene, phenylene, heteroarylene; R1 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl; R2 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl; either R1R2N, or NR1R2L1 = atoms to form a saturated or unsatd. heterocycle possibly containing O, N, S; R3 = H, halo, OH, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkylenedioxy, heterocycle, aryl, heteroaryl; R4, R41, R411, R4111 = H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, oxo; 2 of R4, R41, R411, R4111 may form a ring possibly containing O, N, S; L2 = bond, alkylene, alkenylene, alkynylene, cycloalkylene, O, NR17, CO, SO2; Y = N-heterocycle possibly containing O, N, S; R5 = H, halo, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl; R17 = H, alkyl, cycloalkyl; Q = (CR411R4111)p], were prepared as drugs (no data). Thus, N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethylimidazolidin-1-yl)-2-trifluoromethoxyphenyl]-2-chloroacetamide (preparation given) was heated 1 h at 50° with morpholine to give N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethylimidazolidin-1-yl)-2-trifluoromethoxyphenyl]-2-morpholin-4-ylacetamide.
IT 874952-80-4P 874952-82-6P 874952-85-9P
874952-88-2P 874952-90-6P 874952-93-9P
874952-96-2P 874952-98-4P 874953-01-2P
874953-04-5P 874953-07-8P 874953-10-3P

874953-13-6P 874953-16-9P 874953-19-2P
874953-22-7P 874953-24-9P 874953-26-1P
874953-28-3P 874953-30-7P 874953-32-9P
874953-35-2P 874953-37-4P 874953-38-5P
874953-39-6P 874953-40-9P 874953-41-0P
874953-42-1P 874953-44-3P 874953-46-5P
874953-48-7P 874953-50-1P 874953-52-3P
874953-54-5P 874953-56-7P 874953-59-0P
874953-61-4P 874953-63-6P 874953-65-8P
874953-67-0P 874953-83-0P 874953-84-1P
874953-85-2P 874953-86-3P 874953-89-6P
874953-90-9P 874953-91-0P 874953-92-1P
874953-93-2P 874953-94-3P 874953-95-4P
874953-96-5P 874954-62-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of imidazolidinediones as protein kinase inhibitors)

RN 874952-80-4 CAPLUS
CN 4-Morpholineacetamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 874952-82-6 CAPLUS
CN 4-Morpholineacetamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-2,6-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874952-81-5
CMF C26 H30 F3 N5 O5



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874952-85-9 CAPLUS
CN Acetamide, 2-(cyclopentylamino)-N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874952-84-8
CMF C25 H28 F3 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874952-88-2 CAPLUS
CN Acetamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-2-[(2,2,2-trifluoroethyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874952-87-1
CMF C22 H21 F6 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874952-90-6 CAPLUS
CN Acetamide, 2-(diethylamino)-N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874952-89-3
CMF C24 H28 F3 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874952-93-9 CAPLUS
CN 4-Thiomorpholineacetamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874952-92-8
CMF C24 H26 F3 N5 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874952-96-2 CAPLUS
CN 1-Pyrrolidineacetamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874952-95-1
CMF C24 H26 F3 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874952-98-4 CAPLUS
CN 1-Piperazineacetamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-4-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874952-97-3
CMF C25 H29 F3 N6 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874953-01-2 CAPLUS
CN 1-Piperidineacetamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-00-1
CMF C25 H28 F3 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-04-5 CAPLUS
CN Acetamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-2-[(2-pyridinylmethyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-03-4
CMF C26 H25 F3 N6 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-07-8 CAPLUS
CN Acetamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-2-[(3-pyridinylmethyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-06-7
CMF C26 H25 F3 N6 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-10-3 CAPLUS
CN Acetamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-2-[(4-pyridinylmethyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-09-0
CMF C26 H25 F3 N6 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-13-6 CAPLUS
CN Acetamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-2-[(2-hydroxyethyl)amino]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-12-5
CMF C22 H24 F3 N5 O5



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-16-9 CAPLUS
CN Acetamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-2-[(2-methoxyethyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-15-8
CMF C23 H26 F3 N5 O5



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-19-2 CAPLUS
CN Acetamide, 2-(dimethylamino)-N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-18-1
CMF C22 H24 F3 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-22-7 CAPLUS
CN Acetamide, 2-[(cyanomethyl)amino]-N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-21-6
CMF C22 H21 F3 N6 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-24-9 CAPLUS
CN 1-Piperidineacetamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 874953-26-1 CAPLUS
CN 1H-1,4-Diazepine-1-acetamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]hexahydro-4-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-25-0
CMF C26 H31 F3 N6 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-28-3 CAPLUS
CN Acetamide, 2-(butylamino)-N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-27-2
CMF C24 H28 F3 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-30-7 CAPLUS
CN Acetamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-2-[(1,2,2-trimethylpropyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-29-4
CMF C26 H32 F3 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-32-9 CAPLUS
CN Glycine, N-[2-[[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]amino]-2-oxoethyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-31-8
CMF C23 H24 F3 N5 O6



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-35-2 CAPLUS
CN 1-Piperidineacetamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 874953-37-4 CAPLUS
CN 1-Piperidineacetamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 874953-38-5 CAPLUS
CN 1H-1,4-Diazepine-1-acetamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]hexahydro- (9CI) (CA INDEX NAME)



RN 874953-39-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[2-[[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]amino]-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 874953-40-9 CAPLUS
CN 1-Azetidineacetamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 874953-41-0 CAPLUS
CN Acetamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-2-[(2-fluoroethyl)amino]- (9CI) (CA INDEX NAME)



RN 874953-42-1 CAPLUS
CN Acetamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-2-[(2-methoxyethyl)methylamino]- (9CI) (CA INDEX NAME)



RN 874953-44-3 CAPLUS
CN Glycine, N-[2-[[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]amino]-2-oxoethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-43-2
CMF C22 H22 F3 N5 O6



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-46-5 CAPLUS
CN Acetamide, 2-(cyclohexylamino)-N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-45-4
CMF C26 H30 F3 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-48-7 CAPLUS
CN Acetamide, 2-(cyclopropylamino)-N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-47-6
CMF C23 H24 F3 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-50-1 CAPLUS
CN 4-Morpholinepropanamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-49-8
CMF C25 H28 F3 N5 O5



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-52-3 CAPLUS
CN 4-Morpholinepropanamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-2,6-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-51-2
CMF C27 H32 F3 N5 O5



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-54-5 CAPLUS
CN 1-Piperazinepropanamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-4-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-53-4
CMF C26 H31 F3 N6 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-56-7 CAPLUS
CN 1-Piperidinepropanamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-55-6
CMF C26 H30 F3 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-59-0 CAPLUS
CN 4-Thiomorpholinepropanamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-58-9
CMF C25 H28 F3 N5 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-61-4 CAPLUS
CN 1-Pyrrolidinepropanamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-,

mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-60-3
CMF C25 H28 F3 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-63-6 CAPLUS
CN Propanamide, 3-(cyclopentylamino)-N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-62-5
CMF C26 H30 F3 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-65-8 CAPLUS
CN Propanamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-3-[(2,2,2-trifluoroethyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-64-7
CMF C23 H23 F6 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-67-0 CAPLUS
CN Propanamide, 3-(diethylamino)-N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-66-9
CMF C25 H30 F3 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-83-0 CAPLUS
CN 4-Piperidinecarboxamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-1-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-82-9
CMF C25 H28 F3 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874953-84-1 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[2-(cyclopentylamino)ethoxy]-4-methoxyphenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 874953-85-2 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[2-[(2-furanylmethyl)amino]ethoxy]-4-methoxyphenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 874953-86-3 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[2-[(2-hydroxy-1-phenylethyl)amino]ethoxy]-4-methoxyphenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 874953-89-6 CAPLUS
CN 2,4-Imidazolidinedione, 3-[4-methoxy-3-[2-[[2-(4-morpholinyl)ethyl]amino]ethoxy]phenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 874953-90-9 CAPLUS
CN 2,4-Imidazolidinedione, 3-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 874953-91-0 CAPLUS
CN 2,4-Imidazolidinedione, 3-[4-methoxy-3-[2-[(2-pyridinylmethyl)amino]ethoxy]phenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 874953-92-1 CAPLUS
CN 2,4-Imidazolidinedione, 3-[4-methoxy-3-[2-[(tetrahydro-2H-pyran-4-yl)amino]ethoxy]phenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 874953-93-2 CAPLUS
CN 2,4-Imidazolidinedione, 3-[4-methoxy-3-[2-[(1-methyl-4-piperidinyl)amino]ethoxy]phenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 874953-94-3 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[2-hydroxy-3-[(tetrahydro-2H-pyran-4-yl)amino]propoxy]-4-methoxyphenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 874953-95-4 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[2-hydroxy-3-[(4-pyridinylmethyl)amino]propoxy]-4-methoxyphenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 874953-96-5 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[2-hydroxy-3-[(1-methyl-4-piperidinyl)amino]propoxy]-4-methoxyphenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 874954-62-8 CAPLUS
CN Acetamide, 2-[(2,2-difluoroethyl)amino]-N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874954-61-7
CMF C22 H22 F5 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 874954-08-2P 874954-09-3P 874954-10-6P
874954-12-8P 874954-13-9P 874954-15-1P
874954-16-2P 874954-18-4P 874954-20-8P
874954-21-9P 874954-22-0P 874954-23-1P
874954-24-2P 874954-25-3P 874954-26-4P
874954-29-7P 874954-30-0P 874954-31-1P
874954-32-2P 874954-33-3P 874954-34-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolidinediones as protein kinase inhibitors)

RN 874954-08-2 CAPLUS

CN 3-Piperidinecarboxamide, N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]-1-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874954-07-1
CMF C25 H28 F3 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874954-09-3 CAPLUS
CN 2,4-Imidazolidinedione, 3-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 874954-10-6 CAPLUS
CN 2,4-Imidazolidinedione, 3-[4-methoxy-3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 874954-12-8 CAPLUS
CN 2,4-Imidazolidinedione, 3-[4-methoxy-3-[2-[(2-methoxyethyl)amino]ethoxy]phenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874954-11-7
CMF C27 H32 N4 O5



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874954-13-9 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[2-(cyclopentylamino)ethoxy]-4-methoxyphenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-84-1
CMF C29 H34 N4 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874954-15-1 CAPLUS
CN 2,4-Imidazolidinedione, 3-[4-methoxy-3-[2-[[(5-methyl-3-isoxazolyl)methyl]amino]ethoxy]phenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)-

, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874954-14-0
CMF C29 H31 N5 O5



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874954-16-2 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[2-[(2-furanylmethyl)amino]ethoxy]-4-methoxyphenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-85-2
CMF C29 H30 N4 O5



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874954-18-4 CAPLUS
CN 2,4-Imidazolidinedione, 3-[4-methoxy-3-[2-[[(5-methylpyrazinyl)methyl]amino]ethoxy]phenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874954-17-3
CMF C30 H32 N6 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874954-20-8 CAPLUS
CN 2,4-Imidazolidinedione, 3-[4-methoxy-3-[2-[[2-(4-pyridinyl)ethyl]amino]ethoxy]phenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874954-19-5
CMF C31 H33 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874954-21-9 CAPLUS
CN 2,4-Imidazolidinedione, 3-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-90-9
CMF C28 H32 N4 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874954-22-0 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[2-[(2-hydroxyethyl)amino]ethoxy]-4-methoxyphenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 874954-23-1 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[2-(ethylamino)ethoxy]-4-methoxyphenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 874954-24-2 CAPLUS
CN 2,4-Imidazolidinedione, 3-[4-methoxy-3-[2-[(2-thiazolylmethyl)amino]ethoxy]phenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 874954-25-3 CAPLUS
CN 2,4-Imidazolidinedione, 3-[4-methoxy-3-[2-[[2-(3-pyridinyl)ethyl]amino]ethoxy]phenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 874954-26-4 CAPLUS
CN 2,4-Imidazolidinedione, 3-[4-methoxy-3-[2-[(4-pyridinylmethyl)amino]ethoxy]phenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)-(9CI) (CA INDEX NAME)



RN 874954-29-7 CAPLUS
CN 2,4-Imidazolidinedione, 3-[4-methoxy-3-[2-(3-pyrrolidinylamino)ethoxy]phenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 874954-30-0 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[2-hydroxy-3-(4-methyl-1-piperazinyl)propoxy]-4-methoxyphenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 874954-31-1 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[2-hydroxy-3-[(4-pyridinylmethyl)amino]propoxy]-4-methoxyphenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 874953-95-4
CMF C31 H33 N5 O5



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874954-32-2 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[2-hydroxy-3-(4-morpholinyl)propoxy]-4-methoxyphenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 874954-33-3 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[2-hydroxy-3-(4-pyridinylamino)propoxy]-4-methoxyphenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 874954-34-4 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[2-hydroxy-3-(3-pyrrolidinylamino)propoxy]-4-methoxyphenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



IT 874953-97-6P 874953-98-7P 874953-99-8P
874954-03-7P 874954-04-8P 874954-28-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazolidinediones as protein kinase inhibitors)
RN 874953-97-6 CAPLUS
CN 2,4-Imidazolidinedione, 5,5-dimethyl-3-[3-nitro-4-(trifluoromethoxy)phenyl]-1-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 874953-98-7 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-amino-4-(trifluoromethoxy)phenyl]-5,5-dimethyl-1-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 874953-99-8 CAPLUS
CN Acetamide, 2-chloro-N-[5-[4,4-dimethyl-2,5-dioxo-3-(4-pyridinylmethyl)-1-imidazolidinyl]-2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 874954-03-7 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-(2,2-diethoxyethoxy)-4-methoxyphenyl]-5,5-dimethyl-1-(4-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 874954-04-8 CAPLUS
CN Acetaldehyde, [5-[4,4-dimethyl-2,5-dioxo-3-(4-quinolinylmethyl)-1-imidazolidinyl]-2-methoxyphenoxy]- (9CI) (CA INDEX NAME)



RN 874954-28-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[2-[5-[4,4-dimethyl-2,5-dioxo-3-(4-quinolinylmethyl)-1-imidazolidinyl]-2-methoxyphenoxy]ethyl]amino]-, 1,1-dimethylethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874954-27-5
CMF C33 H41 N5 O6



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:91433 CAPLUS
DN 144:170994
TI Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors for treating cancer and other diseases
IN Strobel, Hartmut; Nemecek, Conception; Lesuisse, Dominique; Ruf, Sven; El-Ahmad, Youssef; Mauger, Jacques; Guessregen, Stefan; Ritter, Kurt; Malleron, Jean-Luc
PA Aventis Pharma S. A., Fr.
SO Eur. Pat. Appl., 37 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1621535	A1	20060201	EP 2004-291903	20040727
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
WO 2006010643	A1	20060202	WO 2005-EP8722	20050725
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI EP 2004-291903	A	20040727		

OS MARPAT 144:170994
AB The invention relates to the products of formula I (wherein R1 = O or NH, p = 0-2; Y and Y1 = alkyl, cycloalkyl, alkylamino, etc.; R2, R2', R3 and R3' = H, halogen, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl and heteroaryl, or 2 of R2, R2', R3 and R3' form, together with the C atom(s) to which they are attached, a carbocyclic or heterocyclic radical; A = a bond, alkylene, alkenyl, alkynyl, CO, SO2, O, NH, NH-alkyl; B =s a saturated or unsatd. monocyclic or bicyclic heterocyclic radical; Y2 = H, halogen, OH, CN, alkyl, alkoxy, etc.) as kinase inhibitors for treating cancer (no biol. data given). Thus, II was prepared in 2 steps from 4-tert-butylphenylamine and 2-methyl-2-[(quinolin-4-ylmethyl)amino]propionic acid Me ester.
IT 874651-46-4P, 5,5-Dimethyl-1-[(pyridin-4-yl)methyl]-3-[4-[(thiophen-2-yl)sulfanyl]phenyl]imidazolidine-2,4-dione trifluoroacetate
874651-48-6P, 3-(4-Phenylsulfonyl-3-chlorophenyl)-5,5-dimethyl-1-[(pyridin-4-yl)methyl]imidazolidine-2,4-dione trifluoroacetate
874651-50-0P, 3-[4-(4-Fluorophenylsulfanyl)phenyl]-5,5-dimethyl-1-[(pyridin-4-yl)methyl]imidazolidine-2,4-dione trifluoroacetate
874651-52-2P, 3-(4-Phenylsulfonylphenyl)-5,5-dimethyl-1-[(pyridin-4-yl)methyl]imidazolidine-2,4-dione trifluoroacetate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; substituted cyclic urea derivs., preparation thereof and

pharmaceutical use thereof as kinase inhibitors for treating cancer and other diseases)

RN 874651-46-4 CAPLUS

CN 2,4-Imidazolidinedione, 5,5-dimethyl-1-(4-pyridinylmethyl)-3-[4-(2-thienylthio)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874651-45-3

CMF C21 H19 N3 O2 S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 874651-48-6 CAPLUS

CN 2,4-Imidazolidinedione, 3-[3-chloro-4-(phenylsulfonyl)phenyl]-5,5-dimethyl-1-(4-pyridinylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874651-47-5

CMF C23 H20 Cl N3 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874651-50-0 CAPLUS
CN 2,4-Imidazolidinedione, 3-[4-[(4-fluorophenyl)thio]phenyl]-5,5-dimethyl-1-(4-pyridinylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874651-49-7
CMF C23 H20 F N3 O2 S

PAGE 1-A



PAGE 2-A

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 874651-52-2 CAPLUS
CN 2,4-Imidazolidinedione, 5,5-dimethyl-3-[4-(phenylsulfonyl)phenyl]-1-(4-pyridinylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 874651-51-1
CMF C23 H21 N3 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:238947 CAPLUS
DN 142:316831
TI Preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors for the treatment of inflammatory diseases
IN Boman, Erik; Ceide, Susana C.; Dahl, Russell; Delaet, Nancy G. J.; Ernst, Justin; Montalban, Antonio G.; Kahl, Jeffrey D.; Larson, Christopher; Miller, Stephen; Nakanishi, Hiroshi; Roberts, Edward; Saiah, Eddine; Sullivan, Robert; Wang, Zhijun
PA Kemia, Inc., USA
SO PCT Int. Appl., 316 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005023761	A2	20050317	WO 2004-US29372	20040910
WO 2005023761	A3	20050714		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004270733	A1	20050317	AU 2004-270733	20040910
CA 2538820	AA	20050317	CA 2004-2538820	20040910
US 2005107399	A1	20050519	US 2004-939324	20040910
EP 1670787	A2	20060621	EP 2004-809707	20040910
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI US 2003-502569P	P	20030911		
US 2003-531234P	P	20031218		
US 2004-575704P	P	20040528		
US 2004-585012P	P	20040702		
WO 2004-US29372	W	20040910		

OS MARPAT 142:316831
AB Title compds., such as I and II (four Markush structures are claimed), wherein X = C(O), C(S) or CH2; G = (un)substituted carbocyclyl or heterocyclyl; Ar = indazolyl, indolyl, pyrazolyl, alkyl, etc.; L = covalent bond or (un)substituted carbon chain; Q = H, (un)substituted amino, cycloalkyl, heterocyclyl, alkoxy or sulfonyl; with some limitations and exclusions, and stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, were prepared as cytokine inhibitors. For instance, cyclization of p-tolylhydrazine hydrochloride with 4,4-dimethyl-3-oxopentanenitrile to the corresponding pyrazolamine (92% yield) followed by EDC-mediated coupling with indazole-3-carboxylic acid gave indazolopyrazole III (40% yield). I were found to have activity in the TNFa ELISA assay, with some compds. having IC50 < 10 μM. Therefore, I and their pharmaceutical compns. are useful in preventing or treating conditions mediated by cytokines, such as arthritis and inflammatory diseases.
IT 848147-35-3P 848148-03-8P 848148-32-3P

848148-65-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitor; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

RN 848147-35-3 CAPLUS
CN Imidazolidinetrione, [5-(1,1-dimethylethyl)-3-isoxazolyl][4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 848148-03-8 CAPLUS
CN Imidazolidinetrione, [3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl][4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 848148-32-3 CAPLUS
CN Imidazolidinetrione, [3-(1,1-dimethylethyl)-1-(3-methylphenyl)-1H-pyrazol-5-yl][4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 848148-65-2 CAPLUS
CN Imidazolidinetrione, [5-(1,1-dimethylethyl)-3-isoxazolyl][4-[[2-(4-morpholinyl)-4-pyrimidinyl]oxy]-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Bu-t
O
N
O
N
O
O
N
O
N
N
O
N

L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:631315 CAPLUS
DN 141:174472
TI Preparation of amino acid-derived cyclic ureas as protein kinase inhibitors and antiproliferative agents
IN Patek, Marcel; Nair, Anil; Hittinger, Augustin; Nemecek, Conception; Bond, Daniel; Harlow, Greg; Bouchard, Herve; Mauger, Jacques; Malleron, Jean Luc; Palermo, Mark
PA Aventis Pharma S.A., Fr.
SO Fr. Demande, 340 pp.
CODEN: FRXXBL
DT Patent
LA French

Appl.

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2850652	A1	20040806	FR 2003-1098	20030131
	AU 2004209319	A1	20040819	AU 2004-209319	20040128
	CA 2513631	AA	20040819	CA 2004-2513631	20040128
	WO 2004070050	A2	20040819	WO 2004-FR188	20040128
	WO 2004070050	A3	20050217		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1599464	A2	20051130	EP 2004-705838	20040128
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2004007091	A	20060124	BR 2004-7091	20040128
	CN 1768054	A	20060503	CN 2004-80008835	20040128
	JP 2006517569	T2	20060727	JP 2006-502123	20040128
	US 2004248884	A1	20041209	US 2004-770382	20040202
	NO 2005004006	A	20051013	NO 2005-4006	20050829
PRAI	FR 2003-1098	A	20030131		
	US 2003-468685P	P	20030507		
	WO 2004-FR188	W	20040128		

OS MARPAT 141:174472

AB Title compds. I [wherein X = (CH2)p; p = 0-2; R, R1 = independently O or NH; R2, R3 = independently H, alk(en/yn)yl, cycloalkyl, (un)substituted hetero/aryl; or R2CR3 = (un)substituted carbocyclyl or heterocyclyl; A1 = a bond, alkyl, allyl, propynyl; when one of Y or Y1 = OCF3, S(O)nCF3, S(O)n-Alk, SO2CHF2, SO2CF2CF3, and SO2NH2 and derivs., the other of Y or Y1 = as defined above, and H, halo, OH and derivs., NH2 and derivs., (un)substituted alkyl, hetero/aryl, CF3, O-allyl, etc.; A2 = A1, CO, SO2; B2 = (un)substituted (un)saturated heterocyclyl; Y2 = H, halo, OH and derivs., NH2 and derivs., SO2NH2 and derivs., CO2H and derivs., (un)substituted O-allyl, O-propynyl, O-cyclo/heterocyclo/cyclo/alkyl, hetero/aryl, etc.; with provisos; their prodrugs, racemates, enantiomers and diastereomers, and their pharmaceutically acceptable acid or base addition salts] were prepared as protein kinase inhibitors (no data) for treating proliferative diseases (no data), in particular neoplasm. For example II•CF3CO2H, was prepared, in 41% yield, by a solid phase synthesis from Fmoc-L-ALa-OH, quinoline-4-carboxaldehyde, 4-(trifluoromethanesulfonyl)aniline, and triphosgene. I are inhibitors of 17 kinase including IGF-1R, AKT, FAK,

etc. (no data).

IT 733807-18-6P, (S)-5-Methyl-1-[(quinolin-4-yl)methyl]-3-[4-(trifluoromethanesulfonyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-20-0P, (S)-5-Methyl-1-[(pyridin-4-yl)methyl]-3-[4-(trifluoromethanesulfonyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-21-1P, (S)-5-Methyl-1-[(quinolin-4-yl)methyl]-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione 733807-22-2P, (S)-5-Methyl-1-[(quinolin-4-yl)methyl]-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-24-4P, 5,5-Dimethyl-1-[(quinolin-4-yl)methyl]-3-[4-(trifluoromethanesulfonyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-26-6P, (R)-5-Methyl-1-[(quinolin-4-yl)methyl]-3-[4-(trifluoromethanesulfonyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-28-8P, (R)-5-Methyl-1-[(quinolin-4-yl)methyl]-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-30-2P, (R)-5-Methyl-1-[(pyridin-4-yl)methyl]-3-[4-(trifluoromethanesulfonyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-32-4P, (R)-5-Methyl-1-(3-methylpyridin-4-ylmethyl)-3-[4-(trifluoromethanesulfonyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-36-8P, (R)-5-Isopropyl-1-[(quinolin-4-yl)methyl]-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-38-0P, (R)-5-Isopropyl-1-[(quinolin-4-yl)methyl]-3-[4-(trifluoromethanesulfonyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-40-4P, (R)-5-(4-Hydroxybenzyl)-1-[(quinolin-4-yl)methyl]-3-[4-(trifluoromethanesulfonyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-42-6P, (R)-5-(4-Hydroxybenzyl)-1-[(pyridin-4-yl)methyl]-3-[4-(trifluoromethanesulfonyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-44-8P 733807-52-8P, (R)-1-(3-Hydroxypyridin-4-ylmethyl)-5-methyl-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-53-9P, 5,5-Dimethyl-1-[(quinolin-4-yl)methyl]-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione 733807-54-0P, 5,5-Dimethyl-1-[(quinolin-4-yl)methyl]-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione trifluoroacetate 733807-56-2P, 5,5-Dimethyl-1-[(quinolin-4-yl)methyl]-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-58-4P, 5,5-Dimethyl-1-(3-methylpyridin-4-ylmethyl)-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione trifluoroacetate 733807-60-8P, 5,5-Dimethyl-1-(3-methylpyridin-4-ylmethyl)-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-62-0P, 5,5-Dimethyl-1-(3-methylpyridin-4-ylmethyl)-3-[4-(trifluoromethanesulfonyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-64-2P, 1-(3-Hydroxypyridin-4-ylmethyl)-5,5-dimethyl-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione trifluoroacetate 733807-66-4P, 1-(3-Hydroxypyridin-4-ylmethyl)-5,5-dimethyl-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-68-6P, 1-(3-Hydroxypyridin-4-ylmethyl)-5,5-dimethyl-3-[4-(trifluoromethanesulfonyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-83-5P, (S)-5-Methyl-1-[(pyridin-4-yl)methyl]-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-85-7P, 1-[(Quinolin-4-yl)methyl]-3-[4-(trifluoromethanesulfonyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-87-9P, (R)-5-Methyl-1-[(pyridin-4-yl)methyl]-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-89-1P, (S)-5-Methyl-1-(3-methylpyridin-4-ylmethyl)-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733807-91-5P, (S)-5-Methyl-1-(3-methylpyridin-4-ylmethyl)-3-[4-(trifluoromethanesulfonyl)phenyl]imidazolidine-2,4-dione trifluoroacetate

733808-01-0P, (R)-5-Methyl-1-(3-methylpyridin-4-ylmethyl)-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733808-03-2P, (R)-5-Benzyl-1-[(quinolin-4-yl)methyl]-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733808-05-4P, (R)-5-Benzyl-1-[(quinolin-4-yl)methyl]-3-[4-(trifluoromethanesulfonyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733808-07-6P, (R)-5-Benzyl-1-[(pyridin-4-yl)methyl]-3-[4-(trifluoromethanesulfonyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733808-09-8P, (R)-5-Isobutyl-1-[(quinolin-4-yl)methyl]-3-[4-(trifluoromethanesulfonyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733808-11-2P, (R)-5-(4-Hydroxybenzyl)-1-[(quinolin-4-yl)methyl]-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733808-13-4P 733808-15-6P, (R)-5-[(Benzo[b]thiophen-3-yl)methyl]-1-[(quinolin-4-yl)methyl]-3-[4-(trifluoromethanesulfonyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733808-17-8P, (R)-5-[(Benzo[b]thiophen-3-yl)methyl]-1-[(pyridin-4-yl)methyl]-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733808-19-0P, (R)-5-[(Benzo[b]thiophen-3-yl)methyl]-1-[(pyridin-4-yl)methyl]-3-[4-(trifluoromethanesulfonyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733808-21-4P, (S)-5-[(Pyridin-2-yl)methyl]-1-[(quinolin-4-yl)methyl]-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733808-23-6P, (S)-5-[(Pyridin-2-yl)methyl]-1-[(quinolin-4-yl)methyl]-3-[4-(trifluoromethanesulfonyl)phenyl]imidazolidine-2,4-dione trifluoroacetate 733808-31-6P, 5,5-Dimethyl-1-[(3-chloro-6-methoxyquinolin-4-yl)methyl]-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione 733808-35-0P, 5,5-Dimethyl-1-[(pyridin-4-yl)methyl]-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione 733808-37-2P, 1-[(Pyridin-4-yl)methyl]-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione 733808-38-3P, 5,5-Dimethyl-1-[(pyridin-4-yl)methyl]-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(kinase inhibitor; preparation of amino acid-derived cyclic ureas as protein kinase inhibitors and antiproliferative agents)

RN 733807-18-6 CAPLUS

CN 2,4-Imidazolidinedione, 5-methyl-1-(4-quinolinylmethyl)-3-[4-[(trifluoromethyl)sulfonyl]phenyl]-, (5S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-17-5
CMF C21 H16 F3 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-20-0 CAPLUS
CN 2,4-Imidazolidinedione, 5-methyl-1-(4-pyridinylmethyl)-3-[4-[(trifluoromethyl)sulfonyl]phenyl]-, (5S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-19-7
CMF C17 H14 F3 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-21-1 CAPLUS
CN 2,4-Imidazolidinedione, 5-methyl-1-(4-quinolinylmethyl)-3-[4-[(trifluoromethyl)thio]phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 733807-22-2 CAPLUS
CN 2,4-Imidazolidinedione, 5-methyl-1-(4-quinolinylmethyl)-3-[4-[(trifluoromethyl)thio]phenyl]-, (5S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-21-1
CMF C21 H16 F3 N3 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-24-4 CAPLUS
CN 2,4-Imidazolidinedione, 5,5-dimethyl-1-(4-quinolinylmethyl)-3-[4-[(trifluoromethyl)sulfonyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-23-3
CMF C22 H18 F3 N3 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-26-6 CAPLUS
CN 2,4-Imidazolidinedione, 5-methyl-1-(4-quinolinylmethyl)-3-[4-[(trifluoromethyl)sulfonyl]phenyl]-, (5R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-25-5
CMF C21 H16 F3 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-28-8 CAPLUS
CN 2,4-Imidazolidinedione, 5-methyl-1-(4-quinolinylmethyl)-3-[4-[(trifluoromethyl)thio]phenyl]-, (5R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-27-7
CMF C21 H16 F3 N3 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-30-2 CAPLUS
CN 2,4-Imidazolidinedione, 5-methyl-1-(4-pyridinylmethyl)-3-[4-[(trifluoromethyl)sulfonyl]phenyl]-, (5R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-29-9
CMF C17 H14 F3 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-32-4 CAPLUS
CN 2,4-Imidazolidinedione, 5-methyl-1-[(3-methyl-4-pyridinyl)methyl]-3-[4-[(trifluoromethyl)sulfonyl]phenyl]-, (5R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-31-3
CMF C18 H16 F3 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-36-8 CAPLUS

CN 2,4-Imidazolidinedione, 5-(1-methylethyl)-1-(4-quinolinylmethyl)-3-[4-[(trifluoromethyl)thio]phenyl]-, (5R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-35-7
CMF C23 H20 F3 N3 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-38-0 CAPLUS
CN 2,4-Imidazolidinedione, 5-(1-methylethyl)-1-(4-quinolinylmethyl)-3-[4-[(trifluoromethyl)sulfonyl]phenyl]-, (5R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-37-9
CMF C23 H20 F3 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-40-4 CAPLUS
CN 2,4-Imidazolidinedione, 5-[(4-hydroxyphenyl)methyl]-1-(4-quinolinylmethyl)-3-[4-[(trifluoromethyl)sulfonyl]phenyl]-, (5R)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-39-1
CMF C27 H20 F3 N3 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-42-6 CAPLUS
CN 2,4-Imidazolidinedione, 5-[(4-hydroxyphenyl)methyl]-1-(4-pyridinylmethyl)-3-[4-[(trifluoromethyl)sulfonyl]phenyl]-, (5R)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-41-5
CMF C23 H18 F3 N3 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-44-8 CAPLUS
CN 2,4-Imidazolidinedione, 5-[(1S)-1-hydroxyethyl]-1-(4-quinolinylmethyl)-3-[4-[(trifluoromethyl)sulfonyl]phenyl]-, (5R)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-43-7
CMF C22 H18 F3 N3 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-52-8 CAPLUS
CN 2,4-Imidazolidinedione, 1-[(3-hydroxy-4-pyridinyl)methyl]-5-methyl-3-[4-[(trifluoromethyl)thio]phenyl]-, (5R)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-51-7
CMF C17 H14 F3 N3 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-53-9 CAPLUS
CN 2,4-Imidazolidinedione, 5,5-dimethyl-1-(4-quinolinylmethyl)-3-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 733807-54-0 CAPLUS
CN 2,4-Imidazolidinedione, 5,5-dimethyl-1-(4-quinolinylmethyl)-3-[4-(trifluoromethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-53-9
CMF C22 H18 F3 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-56-2 CAPLUS
CN 2,4-Imidazolidinedione, 5,5-dimethyl-1-(4-quinolinylmethyl)-3-[4-[(trifluoromethyl)thio]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-55-1
CMF C22 H18 F3 N3 O2 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-58-4 CAPLUS
CN 2,4-Imidazolidinedione, 5,5-dimethyl-1-[(3-methyl-4-pyridinyl)methyl]-3-[4-(trifluoromethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-57-3
CMF C19 H18 F3 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-60-8 CAPLUS
CN 2,4-Imidazolidinedione, 5,5-dimethyl-1-[(3-methyl-4-pyridinyl)methyl]-3-[4-[(trifluoromethyl)thio]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-59-5
CMF C19 H18 F3 N3 O2 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-62-0 CAPLUS
CN 2,4-Imidazolidinedione, 5,5-dimethyl-1-[(3-methyl-4-pyridinyl)methyl]-3-[4-[(trifluoromethyl)sulfonyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-61-9
CMF C19 H18 F3 N3 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-64-2 CAPLUS
CN 2,4-Imidazolidinedione, 1-[(3-hydroxy-4-pyridinyl)methyl]-5,5-dimethyl-3-[4-(trifluoromethoxy)phenyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-63-1
CMF C18 H16 F3 N3 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-66-4 CAPLUS
CN 2,4-Imidazolidinedione, 1-[(3-hydroxy-4-pyridinyl)methyl]-5,5-dimethyl-3-[4-[(trifluoromethyl)thio]phenyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-65-3
CMF C18 H16 F3 N3 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-68-6 CAPLUS
CN 2,4-Imidazolidinedione, 1-[(3-hydroxy-4-pyridinyl)methyl]-5,5-dimethyl-3-[4-[(trifluoromethyl)sulfonyl]phenyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-67-5
CMF C18 H16 F3 N3 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-83-5 CAPLUS
CN 2,4-Imidazolidinedione, 5-methyl-1-(4-pyridinylmethyl)-3-[4-[(trifluoromethyl)thio]phenyl]-, (5S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-82-4
CMF C17 H14 F3 N3 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-85-7 CAPLUS
CN 2,4-Imidazolidinedione, 1-(4-quinolinylmethyl)-3-[4-[(trifluoromethyl)sulfonyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-84-6
CMF C20 H14 F3 N3 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-87-9 CAPLUS
CN 2,4-Imidazolidinedione, 5-methyl-1-(4-pyridinylmethyl)-3-[4-[(trifluoromethyl)thio]phenyl]-, (5R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-86-8
CMF C17 H14 F3 N3 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-89-1 CAPLUS
CN 2,4-Imidazolidinedione, 5-methyl-1-[(3-methyl-4-pyridinyl)methyl]-3-[4-[(trifluoromethyl)thio]phenyl]-, (5S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-88-0
CMF C18 H16 F3 N3 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733807-91-5 CAPLUS
CN 2,4-Imidazolidinedione, 5-methyl-1-[(3-methyl-4-pyridinyl)methyl]-3-[4-[(trifluoromethyl)sulfonyl]phenyl]-, (5S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733807-90-4
CMF C18 H16 F3 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733808-01-0 CAPLUS
CN 2,4-Imidazolidinedione, 5-methyl-1-[(3-methyl-4-pyridinyl)methyl]-3-[4-[(trifluoromethyl)thio]phenyl]-, (5R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733808-00-9
CMF C18 H16 F3 N3 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733808-03-2 CAPLUS
CN 2,4-Imidazolidinedione, 5-(phenylmethyl)-1-(4-quinolinylmethyl)-3-[4-[(trifluoromethyl)thio]phenyl]-, (5R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733808-02-1
CMF C27 H20 F3 N3 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733808-05-4 CAPLUS
CN 2,4-Imidazolidinedione, 5-(phenylmethyl)-1-(4-quinolinylmethyl)-3-[4-[(trifluoromethyl)sulfonyl]phenyl]-, (5R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733808-04-3
CMF C27 H20 F3 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733808-07-6 CAPLUS
CN 2,4-Imidazolidinedione, 5-(phenylmethyl)-1-(4-pyridinylmethyl)-3-[4-[(trifluoromethyl)sulfonyl]phenyl]-, (5R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733808-06-5
CMF C23 H18 F3 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733808-09-8 CAPLUS
CN 2,4-Imidazolidinedione, 5-(2-methylpropyl)-1-(4-quinolinylmethyl)-3-[4-[(trifluoromethyl)sulfonyl]phenyl]-, (5R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733808-08-7
CMF C24 H22 F3 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733808-11-2 CAPLUS
CN 2,4-Imidazolidinedione, 5-[(4-hydroxyphenyl)methyl]-1-(4-quinolinylmethyl)-3-[4-[(trifluoromethyl)thio]phenyl]-, (5R)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 733808-10-1
CMF C27 H20 F3 N3 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733808-13-4 CAPLUS
CN 2,4-Imidazolidinedione, 5-[(1S)-1-hydroxyethyl]-1-(4-quinolinylmethyl)-3-[4-[(trifluoromethyl)thio]phenyl]-, (5R)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 733808-12-3
CMF C22 H18 F3 N3 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733808-15-6 CAPLUS
CN 2,4-Imidazolidinedione, 5-(benzo[b]thien-3-ylmethyl)-1-(4-quinolinylmethyl)-3-[4-[(trifluoromethyl)sulfonyl]phenyl]-, (5R)-,

mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733808-14-5
CMF C29 H20 F3 N3 O4 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733808-17-8 CAPLUS
CN 2,4-Imidazolidinedione, 5-(benzo[b]thien-3-ylmethyl)-1-(4-pyridinylmethyl)-3-[4-[(trifluoromethyl)thio]phenyl]-, (5R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733808-16-7
CMF C25 H18 F3 N3 O2 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733808-19-0 CAPLUS
CN 2,4-Imidazolidinedione, 5-(benzo[b]thien-3-ylmethyl)-1-(4-pyridinylmethyl)-3-[4-[(trifluoromethyl)sulfonyl]phenyl]-, (5R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733808-18-9
CMF C25 H18 F3 N3 O4 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733808-21-4 CAPLUS
CN 2,4-Imidazolidinedione, 5-(2-pyridinylmethyl)-1-(4-quinolinylmethyl)-3-[4-[(trifluoromethyl)thio]phenyl]-, (5S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733808-20-3
CMF C26 H19 F3 N4 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733808-23-6 CAPLUS
CN 2,4-Imidazolidinedione, 5-(2-pyridinylmethyl)-1-(4-quinolinylmethyl)-3-[4-[(trifluoromethyl)sulfonyl]phenyl]-, (5S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 733808-22-5
CMF C26 H19 F3 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733808-31-6 CAPLUS
CN 2,4-Imidazolidinedione, 1-[(3-chloro-6-methoxy-4-quinolinyl)methyl]-5,5-dimethyl-3-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 733808-35-0 CAPLUS
CN 2,4-Imidazolidinedione, 5,5-dimethyl-1-(4-pyridinylmethyl)-3-[4-[(trifluoromethyl)thio]phenyl]- (9CI) (CA INDEX NAME)



RN 733808-37-2 CAPLUS
CN 2,4-Imidazolidinedione, 1-(4-pyridinylmethyl)-3-[4-[(trifluoromethyl)thio]phenyl]- (9CI) (CA INDEX NAME)



RN 733808-38-3 CAPLUS
CN 2,4-Imidazolidinedione, 5,5-dimethyl-1-(4-pyridinylmethyl)-3-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:623736 CAPLUS
DN 142:32428
TI A 3D-QSAR study on C-3 substituted 4,6-dichloroindole-2- carboxylic acids with comparative molecular field analysis
AU Song, Huai-en; Shen, Jian-hua; Wen, Ren; Jiang, Hua-liang
CS Department of Medicinal Chemistry, Fudan University, Shanghai, 200032, Peop. Rep. China
SO Journal of Chinese Pharmaceutical Sciences (2004), 13(2), 119-123
CODEN: JCHSE4; ISSN: 1003-1057
PB Journal of Chinese Pharmaceutical Sciences
DT Journal
LA English
AB Aim and Method: Comparative mol. field anal. (CoMFA), a three dimensional quant. structure-activity relationship (3D-QSAR) method was applied to a novel series of C-3 substituted 4,6-dichloroindole-2-carboxylic acids to study the relationship between their structure and the affinity for the glycine site of the NMDA receptor. Result: The coeffs. of cross-validation q2 and non cross-validation r2 for the model established by the study are 0.744 and 0.993, resp., the value of variance ratio F is 261.343, and standard error estimate (SE) is 0.039. Conclusion: These values indicate that the CoMFA model may have a good prediction for the activity of C-3 substituted 4, 6-dichloroindole-2-carboxylic acids. As a consequence, the predicted, activity values of new designed compds. supports our conclusion from the model.
IT 496956-22-0
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(3D-QSAR study on C-3 substituted 4,6-dichloroindole-2- carboxylic acids with comparative mol. field anal.)
RN 496956-22-0 CAPLUS
CN 1H-Indole-2-carboxylic acid, 4,6-dichloro-3-[[3-(4-methoxyphenyl)-2,4-dioxo-1-imidazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Claim requires a "F" containing substit. at 6-SO2- sub.

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:20322 CAPLUS
DN 140:87658
TI Peptidomimetic modulators of cell adhesion
IN Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie Denise; Wang, Shaomeng; Hu, Zengjian
PA Can.
SO U.S. Pat. Appl. Publ., 280 pp., Cont.-in-part of U.S. Ser. No. 6,982. CODEN: USXXCO
DT Patent
LA English
FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004006011	A1	20040108	US 2003-425557	20030428
	US 6031072	A	20000229	US 1997-893534	19970711
	US 6326352	B1	20011204	US 2000-507102	20000217
	US 2002168761	A1	20021114	US 2001-769145	20010124
	US 2002151475	A1	20021017	US 2001-6982	20011204
	US 6914044	B2	20050705		
PRAI	US 1996-21612P	P	19960712		
	US 1997-893534	A1	19970711		
	US 2000-491078	B2	20000124		
	US 2000-507102	A1	20000217		
	US 2001-769145	B2	20010124		
	US 2001-6982	A2	20011204		

OS MARPAT 140:87658
AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
IT 351857-29-9, 2,4-Imidazolidinedione, 3-[(4-hydroxyphenyl)methyl]-1-(1H-imidazol-4-ylmethyl)-5-methyl-, (5S)-
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
RN 351857-29-9 CAPLUS
CN 2,4-Imidazolidinedione, 3-[(4-hydroxyphenyl)methyl]-1-(1H-imidazol-4-ylmethyl)-5-methyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


HO
O
N
O
S
N
N
N
H
Me

L4 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:977051 CAPLUS
DN 140:199260
TI Traceless synthesis of hydantoin by focused microwave irradiation
AU Lee, Ming-Juan; Sun, Chung-Ming
CS Department of Chemistry, National Dong Hwa University, Shou-Feng, Hualien, 974, Taiwan
SO Tetrahedron Letters (2004), 45(2), 437-440
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 140:199260
AB An efficient, microwave-assisted method for the liquid-phase combinatorial synthesis of 1,3-disubstituted hydantoins, e.g., I, has been developed. Chloroacetyl chloride was directly anchored to HO-PEG-OH and subsequently reacted with various primary amines in a microwave cavity. The PEG bound secondary amine was coupled with isocyanates and concomitant cyclization-cleavage step, occurred under mild basic conditions, by microwave flash heating. The desired products were then liberated from the soluble matrix in good yield and high purity.
IT 662166-86-1P 662166-89-4P
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(microwave-assisted traceless combinatorial preparation of hydantoins via acetylation of PEG-6000 followed by amination with amines, addition to isocyanates, heterocyclization, and resin-cleavage)
RN 662166-86-1 CAPLUS
CN 2,4-Imidazolidinedione, 3-(4-ethoxyphenyl)-1-(2-furanylmethyl)- (9CI) (CA INDEX NAME)



RN 662166-89-4 CAPLUS
CN 2,4-Imidazolidinedione, 3-(4-ethoxyphenyl)-1-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:827586 CAPLUS
DN 140:111233
TI Variations of acidic functions at position 2 and substituents at positions 4, 5 and 6 of the indole moiety and their effect on NMDA-glycine site affinity
AU Jansen, Michaela; Dannhardt, Gerd
CS Institute of Pharmacy, Department of Medicinal and Pharmaceutical Chemistry, Johannes Gutenberg-University, Mainz, 55099, Germany
SO European Journal of Medicinal Chemistry (2003), 38(10), 855-865
CODEN: EJMCA5; ISSN: 0223-5234
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 140:111233
AB The synthetic procedures to obtain indole derivs. with different acidic functions at position 2 of the indole are reported. The synthesized and tested derivs. comprise 5-tetrazolyl, 1,3,4-oxadiazol-5-yl-2-one, and indole-2-carboxylic acid amides with 5-aminotetrazole, methanesulfonamide and trifluoromethanesulfonamide moieties. The binding affinity was evaluated using [3H]MDL 105,519 and pig cortical brain membranes. In general, compds. with acidic functions different from a carboxylic acid moiety are less potent than indole-2-carboxylic acid derivs. Also, the 4,6-dichloro substitution pattern was compared to 5-tert-Bu derivs. and compds. not substituted in the benzene moiety of the indole, indicating that the affinity increases from 5-tert-Bu over unsubstituted to 4,6-dichloro substituted derivs.
IT 648417-16-7P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and structure-activity relationships of indole compds. having variations of acidic functions at position 2 and substituents at positions 4, 5 and 6 of indole moiety and their effect on NMDA-glycine site affinity)
RN 648417-16-7 CAPLUS
CN 1H-Indole-2-carboxylic acid, 5-(1,1-dimethylethyl)-3-[[3-(4-methoxyphenyl)-2,4-dioxo-1-imidazolidinyl]methyl]- (9CI) (CA INDEX NAME)



IT 648417-12-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and structure-activity relationships of indole compds. having variations of acidic functions at position 2 and substituents at positions 4, 5 and 6 of indole moiety and their effect on NMDA-glycine site affinity)
RN 648417-12-3 CAPLUS
CN 1H-Indole-2-carboxylic acid, 5-(1,1-dimethylethyl)-3-[[3-(4-methoxyphenyl)-2,4-dioxo-1-imidazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:507684 CAPLUS
DN 139:85530
TI Preparation of C1 to c4 side-chain modified nodulisporic acid analogs as anthelmintic agents
IN Shih, Thomas; Colletti, Steven L.; Fisher, Michael H.; Meinke, Peter T.; Kuo, Howard C. H.; Chakravarty, Prasun K.; Wyvratt, Matthew J.; Tyagarajan, Sriram; Berger, Richard
PA Merck & Co., Inc., USA
SO U.S., 57 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6586452	B1	20030701	US 2001-901266	20010709
PRAI US 2000-218398P	P	20000714		

OS MARPAT 139:85530
AB Nodulisporic acid derivs., such as I [R1 = H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl; R2-R4 = (substituted) OH; R1R2 = O; R5 = H, (substituted) OH; R4R5 = O; R6-R8 = H, alkyl, alkenyl, aryl, cycloalkyl, halo, CN acyl, amino, etc.] were prepared The compds. were acaricidal, antiparasitic, insecticidal and anthelmintic agents. Thus, nodulisporic acid derivative II was prepared via a multistep synthetic sequence starting from nodulisporic acid A, N-methylhydroxylamine hydrochloride and N-phenyl-maleimide.
IT 552835-16-2P
RL: AGR (Agricultural use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of C1 to c4 side-chain modified nodulisporic acid analogs as anthelmintic agents)
RN 552835-16-2 CAPLUS
CN 2,4-Imidazolidinedione, 1-[(2E)-3-[(3S,4S,4aR,6aS,12aR,13S,15S,16bS,16cS)-2,3,4,4a,5,6,6a,7,10,12,12a,13,14,15,16b,16c-hexadecahydro-3,13-dihydroxy-4,10,10,12,12,16b,16c-heptamethyl-15-(1-methylethenyl)-14-oxo-1H-benz[6,7]indeno[1,2-b]pyrano[3',4':4,5]cyclopenta[1,2-f]pyrrolo[3,2,1-hi]indol-4-yl]-2-propenyl]-3-(4-methoxyphenyl)-5,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:943840 CAPLUS
DN 138:353778
TI Template-directed approach to solid-phase combinatorial synthesis of furan-based libraries
AU Gupta, Priya; Singh, Sanjay K.; Pathak, Arunendra; Kundu, Bijoy
CS Division of Medicinal Chemistry, Central Drug Research Institute, Lucknow, 226001, India
SO Tetrahedron (2002), 58(52), 10469-10474
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 138:353778
AB A novel furan based scaffold 5-(hydroxymethyl)furfural has been identified for the generation of combinatorial libraries using template directed approach on solid phase. The scaffold I (n = 2-4) was based on three dicarboxylic aliphatic acids, butanedioic acid, pentanedioic acid and hexanedioic acid. This scaffold has been utilized to afford furan-based bi-heterocyclic structures with extensive chemical diversity using cycloaddn., multicomponent and cyclization reactions.
IT 518290-29-4P 518290-32-9P 518290-33-0P
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(template-directed approach to solid-phase combinatorial synthesis of furan-based libraries)
RN 518290-29-4 CAPLUS
CN Pentanoic acid, 5-amino-5-oxo-, [5-[[3-(4-ethoxyphenyl)-2,4-dioxo-1-imidazolidinyl]methyl]-2-furanyl]methyl ester (9CI) (CA INDEX NAME)



RN 518290-32-9 CAPLUS
CN Butanoic acid, 4-amino-4-oxo-, [5-[[3-(4-ethoxyphenyl)-2,4-dioxo-1-imidazolidinyl]methyl]-2-furanyl]methyl ester (9CI) (CA INDEX NAME)



RN 518290-33-0 CAPLUS
CN Hexanoic acid, 6-amino-6-oxo-, [5-[[3-(4-ethoxyphenyl)-2,4-dioxo-1-imidazolidinyl]methyl]-2-furanyl]methyl ester (9CI) (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:928396 CAPLUS
DN 138:170038
TI Hydantoin-Substituted 4,6-Dichloroindole-2-Carboxylic Acids as Ligands with High Affinity for the Glycine Binding Site of the NMDA Receptor
AU Jansen, Michaela; Potschka, Heidrun; Brandt, Claudia; Loescher, Wolfgang; Dannhardt, Gerd
CS Institut fuer Pharmazie, Johannes Gutenberg-Universitaet, Mainz, D-55099, Germany
SO Journal of Medicinal Chemistry (2003), 46(1), 64-73
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 138:170038
AB A novel series of C-3 substituted 4,6-dichloroindole-2-carboxylic acids was synthesized to investigate the influence of different hydrogen-bond donor and acceptor groups at this specific position on the affinity to the glycine site of the NMDA receptor. These novel 3-indolylmethyl derivs. with ring-open (amines, sulfonamides, amides, ureas) and cyclic substituents (imidazolidin-2-ones, (thio)hydantoins) led to the discovery that compds. bearing a hydantoin substituent at the C-3 position, e.g., I, of the indole nucleus are the most promising ones. In this series the hydantoins, ureas, and imidazolidin-2-ones were identified as very potent inhibitors of the binding of the glycine site specific ligand [3H]MDL 105,519 to pig cortical brain membranes. Since the hydantoins can be produced via a versatile synthetic approach, further amendments of the hydantoin-substituted compds. were conducted to elucidate the influence of aromatic and aliphatic moieties at position 3 of the hydantoin as well as of sterically hindered compds. (5-substituted hydantoins). On the basis of the pharmacol. data obtained in displacement expts. with [3H]MDL 105,519 and the emerging structure-activity relationships, the data confirms the existing pharmacophore model that suggests a hydrogen-bond acceptor and an aromatic substituent at position 3 of the indole as the key features for high affinity. Log P values indicate brain permeability and selected compds.. showed anticonvulsant activity in vivo. Binding studies for the sodium channel (site 2) were also performed on some selected compds.
IT 496956-22-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and NMDA receptor affinity of dichloroindolecarboxylic acid derivs. via reductive amination of dichloroformylindole carboxylate with amino acid esters, condensation with iso(thio)cyanates, cyclization and hydrolysis)
RN 496956-22-0 CAPLUS
CN 1H-Indole-2-carboxylic acid, 4,6-dichloro-3-[[3-(4-methoxyphenyl)-2,4-dioxo-1-imidazolidinyl]methyl]- (9CI) (CA INDEX NAME)



IT 496956-05-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and NMDA receptor affinity of dichloroindolecarboxylic acid derivs. via reductive amination of dichloroformylindole carboxylate with amino acid esters, condensation with iso(thio)cyanates, cyclization and hydrolysis)

RN 496956-05-9 CAPLUS

CN 1H-Indole-2-carboxylic acid, 4,6-dichloro-3-[[3-(4-methoxyphenyl)-2,4-dioxo-1-imidazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:869496 CAPLUS
DN 137:363033
TI Peptidomimetic modulators of cell adhesion
IN Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie D.; Wang, Shoameng; Hu, Zenjian
PA Can.
SO U.S. Pat. Appl. Publ., 309 pp., Cont.-in-part of U.S. Ser. No. 491,078.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002168761	A1	20021114	US 2001-769145	20010124
	US 2004058864	A1	20040325	US 2003-412701	20030410
	US 2004006011	A1	20040108	US 2003-425557	20030428
PRAI	US 2000-491078	A2	20000124		
	US 1996-21612P	P	19960712		
	US 1997-893534	A1	19970711		
	US 2000-507102	A1	20000217		
	US 2001-769145	B1	20010124		
	US 2001-6982	A2	20011204		

OS MARPAT 137:363033
AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
IT 351857-29-9, 2,4-Imidazolidinedione, 3-[(4-hydroxyphenyl)methyl]-1-(1H-imidazol-4-ylmethyl)-5-methyl-, (5S)-
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
RN 351857-29-9 CAPLUS
CN 2,4-Imidazolidinedione, 3-[(4-hydroxyphenyl)methyl]-1-(1H-imidazol-4-ylmethyl)-5-methyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:545724 CAPLUS
DN 135:147398
TI Peptidomimetic modulators of cell adhesion
IN Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie Denise; Wang, Shoameng; Hu, Zengjian
PA Adherex Technologies, Inc., Can.
SO PCT Int. Appl., 416 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001053331	A2	20010726	WO 2001-US2508	20010124
	WO 2001053331	A3	20020711		
	WO 2001053331	C2	20021031		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-491078 A 20000124
OS MARPAT 135:147398
AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
IT 351857-29-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptidomimetic modulators of cell adhesion)
RN 351857-29-9 CAPLUS
CN 2,4-Imidazolidinedione, 3-[(4-hydroxyphenyl)methyl]-1-(1H-imidazol-4-ylmethyl)-5-methyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


HO
O
N
O
S
N
N
N
H
Me

L4 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:101103 CAPLUS
DN 134:163050
TI Preparation of hydantoin, thiohydantoin, pyrimidinedione, and thioxopyrimidinone derivatives and their affinity for somatostatin receptors
IN Poitout, Lydie; Thurieau, Christophe; Brault, Valerie
PA Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S, Fr.
SO PCT Int. Appl., 166 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001009090	A2	20010208	WO 2000-FR2164	20000728
	WO 2001009090	A3	20020808		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2796945	A1	20010202	FR 1999-9886	19990730
	FR 2796945	B1	20020628		
	CA 2380070	AA	20010208	CA 2000-2380070	20000728
	AU 2000070091	A5	20010219	AU 2000-70091	20000728
	AU 779357	B2	20050120		
	BR 2000012852	A	20020430	BR 2000-12852	20000728
	EP 1246807	A2	20021009	EP 2000-958634	20000728
	EP 1246807	B1	20051102		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	NZ 516718	A	20030429	NZ 2000-516718	20000728
	JP 2003518011	T2	20030603	JP 2001-514294	20000728
	AT 308525	E	20051115	AT 2000-958634	20000728
	ES 2252051	T3	20060516	ES 2000-958634	20000728
	RU 2277093	C2	20060527	RU 2002-105024	20000728
	US 6759415	B1	20040706	US 2002-48144	20020123
	NO 2002000463	A	20020213	NO 2002-463	20020129
	HK 1052510	A1	20050429	HK 2003-104848	20030708
	US 2004209908	A1	20041021	US 2004-813139	20040330
PRAI	FR 1999-9886	A	19990730		
	WO 2000-FR2164	W	20000728		
	US 2002-48144	A3	20020123		

OS MARPAT 134:163050
AB The title compds. I [R1 = carbocyclic or heterocyclic aryl radical optionally substituted or a nonarom. heterocyclic radical optionally substituted; R2 = H, alkyl, aryl; R3 = H, (CH2)pZ3, Z3 = alkyl, cycloalkyl, bisarylalkyl, diaryalkyl, Y1(CH2)p-phenyl-(X1)n, carbocyclic or heterocyclic aryl, nonarom. heterocyclic radical, X1 = H, Cl, F, Br, I, CF3, NO2, OH, NH2, CN, N3, OCF3, alkyl, alkoxy, S-alkyl, (CH2)pNH2, (CH2)pNH-alkyl, (CH2)pN-dialkyl; Y1 = O, S, NH, -; R4 = (CH2)pZ4, Z4 = amino, alkylamino, N,N-dialkylamino; R5 = H, alkyl; X = O, S; p 0-6; q =

1-5; n = 0, 1; provided that when n represents 0, m represents 1, 2 or 3, and when n represents 1, m represents 0 or 1], useful for treating pathol. conditions or diseases wherein somatostatin receptors are involved, were prepared E.g., benzyl (2S)-2-amino-3-(4-phenyl-1H-imidazol-2-yl)propanoate was prepared

IT 325126-36-1P 325126-37-2P 325126-38-3P
325126-53-2P 325126-56-5P 325126-57-6P
325126-58-7P 325126-73-6P 325127-17-1P
325127-18-2P 325127-19-3P 325127-26-2P
325127-37-5P 325127-38-6P 325127-39-7P
325127-46-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydantoin, thiohydantoin, pyrimidinedione, and thioxopyrimidinone derivs. and their affinity for somatostatin receptors)

RN 325126-36-1 CAPLUS

CN 2,4-Imidazolidinedione, 1-(1H-indol-3-ylmethyl)-3-(4-methoxyphenyl)-5-[2-(4-phenyl-1H-imidazol-2-yl)ethyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 325126-37-2 CAPLUS

CN 2,4-Imidazolidinedione, 1-(1H-indol-3-ylmethyl)-3-[4-(methylthio)phenyl]-5-[2-(4-phenyl-1H-imidazol-2-yl)ethyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 325126-38-3 CAPLUS
CN 2,4-Imidazolidinedione, 1-(1H-indol-3-ylmethyl)-5-[2-(4-phenyl-1H-imidazol-2-yl)ethyl]-3-[4-(trifluoromethoxy)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 325126-53-2 CAPLUS
CN 2,4-Imidazolidinedione, 1-(1H-indol-3-ylmethyl)-5-[2-(4-phenyl-1H-imidazol-2-yl)ethyl]-3-(3,4,5-trimethoxyphenyl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 325126-56-5 CAPLUS
CN 2,4-Imidazolidinedione, 3-(4-methoxyphenyl)-5-[2-(4-phenyl-1H-imidazol-2-yl)ethyl]-1-(3-thienylmethyl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 325126-57-6 CAPLUS
CN 2,4-Imidazolidinedione, 3-[4-(methylthio)phenyl]-5-[2-(4-phenyl-1H-imidazol-2-yl)ethyl]-1-(3-thienylmethyl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 325126-58-7 CAPLUS
CN 2,4-Imidazolidinedione, 5-[2-(4-phenyl-1H-imidazol-2-yl)ethyl]-1-(3-thienylmethyl)-3-[4-(trifluoromethoxy)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 325126-73-6 CAPLUS

CN 2,4-Imidazolidinedione, 5-[2-(4-phenyl-1H-imidazol-2-yl)ethyl]-1-(3-thienylmethyl)-3-(3,4,5-trimethoxyphenyl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 325127-17-1 CAPLUS
CN 2,4-Imidazolidinedione, 1-(1H-indol-3-ylmethyl)-3-(4-methoxyphenyl)-5-[(4-phenyl-1H-imidazol-2-yl)methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 325127-18-2 CAPLUS
CN 2,4-Imidazolidinedione, 1-(1H-indol-3-ylmethyl)-3-[4-(methylthio)phenyl]-5-[(4-phenyl-1H-imidazol-2-yl)methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 325127-19-3 CAPLUS
CN 2,4-Imidazolidinedione, 1-(1H-indol-3-ylmethyl)-5-[(4-phenyl-1H-imidazol-2-yl)methyl]-3-[4-(trifluoromethoxy)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 325127-26-2 CAPLUS
CN 2,4-Imidazolidinedione, 1-(1H-indol-3-ylmethyl)-5-[(4-phenyl-1H-imidazol-2-yl)methyl]-3-(3,4,5-trimethoxyphenyl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 325127-37-5 CAPLUS
CN 2,4-Imidazolidinedione, 3-(4-methoxyphenyl)-5-[(4-phenyl-1H-imidazol-2-yl)methyl]-1-(3-thienylmethyl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 325127-38-6 CAPLUS
CN 2,4-Imidazolidinedione, 3-[4-(methylthio)phenyl]-5-[(4-phenyl-1H-imidazol-2-yl)methyl]-1-(3-thienylmethyl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 325127-39-7 CAPLUS
CN 2,4-Imidazolidinedione, 5-[(4-phenyl-1H-imidazol-2-yl)methyl]-1-(3-thienylmethyl)-3-[4-(trifluoromethoxy)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 325127-46-6 CAPLUS
CN 2,4-Imidazolidinedione, 5-[(4-phenyl-1H-imidazol-2-yl)methyl]-1-(3-thienylmethyl)-3-(3,4,5-trimethoxyphenyl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:430794 CAPLUS
DN 127:135767
TI Solid phase synthesis of hydantoin libraries using a novel cyclization and traceless cleavage step
AU Kim, Sang Woong; Ahn, Sang Youl; Koh, Jong Sung; Lee, Jin Ho; Ro, Seonggu; Cho, Hae Yeon
CS Biotech Res. Inst., LG Chemical Ltd./Research Park Sci. Town, Taejon, 305-380, S. Korea
SO Tetrahedron Letters (1997), 38(26), 4603-4606
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier
DT Journal
LA English
OS CASREACT 127:135767
AB N,N-disubstituted hydantoin libraries were constructed using derivs. of amino acids, aromatic aldehydes, and isocyanates. The cyclization to hydantoins was a novel, fast, and clean reaction and was completed within five min to 1 h with neat diisopropylamine. All library compds. were obtained in excellent yield with high purity even after 5 steps.
IT 193144-93-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(solid phase synthesis of hydantoin libraries using a novel cyclization and traceless cleavage step)
RN 193144-93-3 CAPLUS
CN 2,4-Imidazolidinedione, 1-(1,3-benzodioxol-5-yl)-3-(4-ethoxyphenyl)-5-(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1977:44409 CAPLUS
DN 86:44409
TI N-(3-Hydroxyarylpropyl)imides as stabilizers for organic polymers
IN Lind, Hanns
PA Ciba-Geigy A.-G., Switz.
SO Patentschrift (Switz.), 8 pp. Division of Swiss 579,549.
CODEN: SWXXAS
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CH 579607	A	19760915	CH 1976-1177	19730411
PRAI	CH 1976-1177	A	19730411		

AB Light- and heat-resistant polypropylene (I) [9003-07-0] compns. contained barbituric acid, hydantoin, isocyanuric acid, phthalimide, and succinimide derivs. containing N-[3,5,4-RR'(HO)C6H2CH2CH(OR2)CH2] group [R = Me3C, Me2CH; R1 = Me, Me3C, Me2CH; R2 = H, Ac, stearoyl, 3,5,4-(Me3C)3(HO)C6H2CH2CH2CO]. For example, a 1 mm-thick I press molding containing 0.2 phr 1,3-bis[[2-hydroxy-3-(3,5-di-tert-butyl-4-hydroxyphenyl)propyl] 5,5-diethylbarbiturate (II) [54524-79-7] had heat resistance (149°) 40 days, compared with <1 for control not containing II.

IT 54524-80-0
RL: USES (Uses)
(light and heat stabilizers, for polypropylene)

RN 54524-80-0 CAPLUS
CN 2,4-Imidazolidinedione, 1,1'-methylenebis[3-[3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-2-hydroxypropyl]-5,5-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L4 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1975:112710 CAPLUS
DN 82:112710
TI Heat stabilizers for polypropene
IN Lind, Hanns
PA Ciba-Geigy A.-G.
SO Ger. Offen., 66 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2414417	A1	19741031	DE 1974-2414417	19740326
	CH 579549	A	19760915	CH 1973-5163	19730411
	US 3956298	A	19760511	US 1974-452763	19740319
	CA 1023739	A1	19780103	CA 1974-195363	19740319
	NL 7404072	A	19741015	NL 1974-4072	19740326
	FR 2225427	A1	19741108	FR 1974-12584	19740410
	GB 1416848	A	19751210	GB 1974-15813	19740410
	IT 1007843	A	19761030	IT 1974-21219	19740410
	JP 50009644	A2	19750131	JP 1974-41580	19740411
	US 31002	E	19820727	US 1978-904640	19780510
PRAI	CH 1973-5163	A	19730411		
	CH 1974-1624	A	19740206		
	US 1974-452763	A5	19740319		

OS MARPAT 82:112710
AB Derivs. of imides, isocyanurates, hydantoins, and barbiturates, e.g. I, II, III, IV [R = e.g. 4,3,5-HO(Me3C)2C6H2CH2(OH)CH2], were prepared and used as heat stabilizers for polypropene [9003-07-0]. Thus, a mixture of 3,5-di-tert-butyl-4-hydroxybenzyloxirane and 5,5-diethylbarbituric acid of molar ratio 2:1 was heated for 18 hr at 150-5° in DMF to give 1,3-bis[2-hydroxy-3-(3,5-di-tert-butyl-4-hydroxyphenyl)propyl]-5,5-diethyl-2,4,6(1H,3H,5H)pyrimidinetrione (V) [54524-79-7]. Decomposition of 100 g polypropene containing 0.2 g V at 135° was observed after 183 days compared with 3 days for polypropene containing no stabilizer.
IT 54524-80-0P
RL: PREP (Preparation)
(preparation of)
RN 54524-80-0 CAPLUS
CN 2,4-Imidazolidinedione, 1,1'-methylenebis[3-[3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-2-hydroxypropyl]-5,5-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



```
=> => d his

     (FILE 'HOME' ENTERED AT 18:36:01 ON 25 OCT 2006)

     FILE 'REGISTRY' ENTERED AT 18:36:13 ON 25 OCT 2006
L1             STRUCTURE UPLOADED
L2               2 S L1 SSS SAM
L3             257 S L1 SSS FUL

     FILE 'CAPLUS' ENTERED AT 18:38:05 ON 25 OCT 2006
L4              17 S L3

     FILE 'CAOLD' ENTERED AT 18:38:42 ON 25 OCT 2006

=> s l3
L5               0 L3

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    0.44     255.80

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00     -12.75

STN INTERNATIONAL LOGOFF AT 18:38:52 ON 25 OCT 2006
```